X
Jul 28, 2021 08:26 PM (GMT+8) · EqualOcean
Today, Shanghai Chengyi Biotechnology Co., Ltd. announced the start of phase 1A clinical trial to evaluate the oral SSAO / VAP-1 inhibitor ecc0509 as a potential new drug for the treatment of nonalcoholic steatohepatitis (NASH) and osteoarthritis (OA) - related pain. The aim of this trial was to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ecc0509 in healthy volunteers. Preliminary clinical trial data are expected to be completed in the first quarter of 2022.

This text is a result of machine translation.